Douglas M Potter

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients
    Douglas M Potter
    Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
    J Immunol Methods 376:108-12. 2012
  2. pmc Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus
    Lazar Vujanovic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Immunol Immunother 58:121-33. 2009
  3. pmc Multiplex serum biomarker assessments: technical and biostatistical issues
    Lisa H Butterfield
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Transl Med 9:173. 2011
  4. pmc Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC
    Hideho Okada
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    Clin Cancer Res 21:286-94. 2015
  5. pmc LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 19:1816-26. 2013
  6. pmc MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
    Takashi Kimura
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 6:18-26. 2013
  7. doi A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer
    Rajesh Sehgal
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Clin Colorectal Cancer 10:117-20. 2011
  8. pmc Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 106:10746-51. 2009
  9. pmc Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer
    Ann Willman Silk
    University of Pittsburgh, School of Medicine and Clinical Scientist Training Program, Pittsburgh, PA 15232, United States
    Mol Immunol 47:52-6. 2009
  10. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008

Collaborators

Detail Information

Publications10

  1. pmc Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients
    Douglas M Potter
    Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
    J Immunol Methods 376:108-12. 2012
    ..We describe a new study of the association of serum biomarker level with overall survival in melanoma patients, and the problems encountered in carrying it out...
  2. pmc Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus
    Lazar Vujanovic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Immunol Immunother 58:121-33. 2009
    ..These data identify molecular changes in AdV-transduced DC (AdV/DC) that could influence T cell priming and should be considered in design of cancer vaccines...
  3. pmc Multiplex serum biomarker assessments: technical and biostatistical issues
    Lisa H Butterfield
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Transl Med 9:173. 2011
    ..Many of these studies seek biomarkers among circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been identified which can impact the resulting data...
  4. pmc Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC
    Hideho Okada
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    Clin Cancer Res 21:286-94. 2015
    ....
  5. pmc LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma
    Jacky T Yeung
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 19:1816-26. 2013
    ..In this study, we examined the prevalence of these LOH events and their relations with overall survival in GBM...
  6. pmc MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
    Takashi Kimura
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 6:18-26. 2013
    ..g., high levels of MDSC) might already exist in some individuals, suggesting an even earlier premalignant stage or preselection of nonimmunosuppressed patients for prophylactic vaccination...
  7. doi A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer
    Rajesh Sehgal
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Clin Colorectal Cancer 10:117-20. 2011
    ..A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)...
  8. pmc Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 106:10746-51. 2009
    ..This study suggests development of novel miR-targeted therapy to promote cytolysis of tumor cells...
  9. pmc Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer
    Ann Willman Silk
    University of Pittsburgh, School of Medicine and Clinical Scientist Training Program, Pittsburgh, PA 15232, United States
    Mol Immunol 47:52-6. 2009
    ..045 OD vs. 0.030 OD; p=0.017). Our data support further studies into the potential role of anti-MUC1 immunity in preventing progression of premalignant colon lesions to colon cancer...
  10. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...